Page 107 - Read Online
P. 107
Page 12 of 16 Cadamuro et al. Hepatoma Res 2022;8:11 https://dx.doi.org/10.20517/2394-5079.2021.140
Conflicts of interest
All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2022.
REFERENCES
1. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013;11:13-
21.e1; quiz e3. DOI PubMed PMC
2. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79. DOI PubMed PMC
3. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev
Gastroenterol Hepatol 2020;17:557-88. DOI PubMed PMC
4. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver
Int 2006;26:1047-53. DOI PubMed
5. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84. DOI PubMed PMC
6. Choi J, Ghoz HM, Peeraphatdit T, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology 2016;64:785-96. DOI PubMed
PMC
7. Zhang H, Zhu B, Zhang H, Liang J, Zeng W. HBV Infection status and the risk of cholangiocarcinoma in Asia: a meta-analysis.
Biomed Res Int 2016;2016:3417976. DOI PubMed PMC
8. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a
systematic review and meta-analysis. J Hepatol 2020;72:95-103. DOI PubMed
9. Limpaiboon T, Krissadarak K, Sripa B, et al. Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with
poor prognosis. Cancer Letters 2002;181:215-22. DOI PubMed
10. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic
cholangiocarcinoma. Clin Cancer Res 2016;22:291-300. DOI PubMed
11. Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology 2021;74:1429-
44. DOI PubMed PMC
12. Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int
2019;39 Suppl 1:63-78. DOI PubMed
13. Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision
medicine. J Autoimmun 2019;100:17-26. DOI PubMed
14. Lee JI, Campbell JS. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 2014;61:432-4. DOI
PubMed
15. Cadamuro M, Stecca T, Brivio S, et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim
Biophys Acta Mol Basis Dis 2018;1864:1435-43. DOI PubMed PMC
16. Høgdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends
Cancer 2018;4:239-55. DOI PubMed
17. Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive
microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. DOI PubMed PMC
18. Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci
2014;71:1279-88. DOI PubMed PMC
19. Terada T, Kitamura Y, Nakanuma Y. Normal and abnormal development of the human intrahepatic biliary system: a review. Tohoku
J Exp Med 1997;181:19-32. DOI PubMed
20. Brown LF, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with
luminal epithelial surfaces. Mol Biol Cell 1992;3:1169-80. DOI PubMed PMC
21. Zeng J, Liu Z, Sun S, et al. Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells.
Oncol Lett 2018;15:8681-6. DOI PubMed PMC
22. Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M. Tenascin expression at the invasive front is associated
with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 2003;16:1019-27. DOI PubMed
23. Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor
prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992-2000. DOI PubMed
24. Liu Y, Cao L, Chen R, et al. Osteopontin promotes hepatic progenitor cell expansion and tumorigenicity via activation of β-catenin in